The Shareholders Foundation announces that an investor, who purchased shares of AEterna Zentaris Inc. (USA) (NASDAQ:AEZS), filed a lawsuit in the U.S. District Court for the District of New Jersey over alleged violations of Federal Securities Laws by AEterna Zentaris Inc. in connection with certain allegedly false and misleading statements made between October 18, 2012 […]
MolMed NGRhTNF ASCO New Data Show Significantly Extended Survival
A statistically significant 40% improvement of both overall survival and progression-free survival in a large population of patients, identified by a pre-specified analysis on the prior treatment-free interval, and who presented a very dismal prognosis was reported by MolMed S.p.A. (MLM.MI) this weekend, at the 50th ASCO annual meeting. These efficacy results were observed in […]
MolMed TK ASCO new data from the pivotal Phase III randomized trial TK008
MolMed S.p.A. (MLM.MI) provided at the 50th ASCO annual meeting new data from the ongoing randomised pivotal Phase III study on its cell therapy product TK for high-risk acute leukaemia patients transplanted from partially matched (haplo-identical) donors. The intent-to-treat analysis of the first 24 patients treated with TK indicates a 74% 1-year disease free survival […]
TK submission for Conditional Approval validated by EMA
MolMed S.p.A. (Milan:MLM) announces that the European Medicines Agency (EMA) has validated the submission of the Conditional Marketing Authorisation for TK, a novel proprietary investigational cell-gene therapy. The data review of the submitted dossier starts today. TK is an adjunctive treatment in hematopoietic stem cell transplantation for patients affected by high risk leukaemia. TK has […]
MolMed TK therapy submitted for Conditional Marketing Authorisation in EU
MolMed S.p.A. (Milan:MLM) announces that the Company has filed to the European Medicines Agency an application for Conditional Marketing Authorisation for TK, its novel investigational cell-gene therapy. TK is an adjunctive treatment in hematopoietic stem cell transplantation (HSCT) for patients affected by high risk leukaemia. It is estimated that in EU approximately 5,000 leukaemia patients/year […]
Will High-Doses Of Vitamin E Be Found To Delay Alzheimer’s?
There’s a new report in the Tuesday, December 31, 2013 HealthDay News that there may be some good news on the horizon in the fight against Alzheimer’s disease. A study is suggesting a large dose of Vitamin E might help to slow down the progression of this terrible memory-robbing illness. As I read this in […]
- « Previous Page
- 1
- …
- 15
- 16
- 17
- 18
- 19
- …
- 21
- Next Page »